As influenza viruses approach the Northern Hemisphere during the COVID-19 pandemic, many people are questioning which flu shot will perform best with the pending coronavirus vaccines becoming available.
Two companies believe they have a solution to this pending quandary.
Massachusetts-based Vaxess Technologies has formed a partnership with the Taiwanese pharmaceutical company, Medigen Vaccine Biologics to develop a combined COVID-19 and quadrivalent seasonal influenza vaccine, delivered via the novel MIMIX patch system.
Read More
![](https://covid19.healthcare.pro/wp-content/uploads/2020/11/ousa-chea-gKUC4TMhOiY-unsplash.jpg)